[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncologic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncologic-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,82,105,131,157,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100622757","muscle-deterioration-in-hospitalized-cancer-patient-100622757",false,"NCT07387770","Muscle Deterioration in Hospitalized Cancer Patient","Assessment of Muscle Deterioration in Hospitalized Cancer Patients Using Surface Electromyography, Dynamometry, and Bioimpedance","MUSONC","Inclusion Criteria:\n\n* Age: more than 18 years\n* Confirmed malignant neoplasm diagnosis\n* Hospitalization anticipated for at least 4 days\n* Capacity to provide informed consent and complete questionnaires\n* ECOG performance status 0-3\n* Ability to perform voluntary contractions of upper and lower extremities\n\nExclusion Criteria:\n\n* Medical contraindications to strength testing (recent fractures, acute injuries) - Severe neurological impairment precluding functional assessment\n* Implanted electronic devices (relative contraindication for bioimpedance)\n* Severe cognitive impairment preventing questionnaire completion\n* Extensive skin lesions preventing electrode placement for sEMG","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer cachexia and skeletal muscle deterioration represent significant challenges in oncology, affecting up to 42% of cancer patients and correlating with poor clinical outcomes, increased treatment toxicity, and reduced overall survival. Early identification of patients at risk through comprehensive musculoskeletal assessment is essential for timely therapeutic intervention.\n\nThis paper presents a detailed protocol for the longitudinal evaluation of skeletal muscle deterioration in hospitalized cancer patients using an integrated, multimodal approach. The protocol combines validated questionnaires (SARC-F, MSAS, EORTC QLQ-C30, and PSQI), functional measurements (handgrip strength), body composition analysis (bioelectrical impedance analysis), neuromuscular assessment (surface electromyography), and serum biomarkers (basic panel approach).\n\nThe study aims to recruit 45-50 patients with confirmed malignancy requiring hospitalization for ≥4 days, with daily functional measurements and biomarker evaluations at admission and discharge. The protocol prioritizes methodological rigor in vulnerable populations, incorporates standardized procedures for real-world clinical settings, and emphasizes quality control measures.\n\nExpected outcomes include the identification of longitudinal patterns of muscle deterioration, validation of serum biomarker signatures for cachexia detection, and characterization of neuromuscular fatigue patterns using surface electromyography. This comprehensive framework addresses current gaps in skeletal muscle assessment during acute hospitalization and provides a foundation for future interventional studies. The protocol adheres to international ethical standards and considerations for research in vulnerable populations.",[27],"Oncologic Diseases",[29,30,31,32,33,34,35],"cancer cachexia","sarcopenia","surface electromyography","bioimpedance analysis","hospitalized patients","protocol","muscle deterioration","NOT_YET_RECRUITING","2026-05-18",{"date":39,"type":40},"2026-05-19","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"University of Salamanca","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":79,"locationsCount":81},"100623855","implementation-and-evaluation-of-a-program-aimed-at-facilitating-palliative-care-conversations-100623855","NCT07402057","Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations","Implementation and Evaluation of \"My Care My Voice\": a Program Aimed at Facilitating Conversations About Topics Such as Palliative Care","MCMV","Inclusion Criteria (physician):\n\n* Oncologist (medical oncologist, radiation oncologist, etc.), radiologist, organ specialist, nuclear medicine physician, ASO\n* The physician regularly interacts with people with advanced cancer\n* The physician is employed in an oncology hospital department\n\nExclusion Criteria (physician):\n\n* The physician works mostly (\\>50% of the time) in a hospital not involved in this study\n\nInclusion Criteria (healthcare provider - potential implementer):\n\n* Healthcare provider (e.g., study coordinator, oncology coach) or another hospital staff member (e.g., administrative staff)\n* The implementer regularly interacts with people with advanced cancer\n\nExclusion criteria (healthcare provider - potential implementer):\n\n\\- Physician participating in My Care, My Voice\n\nInclusion Criteria (patient):\n\n* The participant is an adult (18 years or older)\n* The participant has been diagnosed with advanced (i.e., non-curable) cancer (no curative treatment ongoing or planned). Participants receiving life-prolonging treatment are included.\n* The participant is aware of their diagnosis and treatment options as determined by their physician\n* The participant has known their initial diagnosis for more than one month\n* The participant is able to participate in a Dutch-language study\n* The participant is competent and able to voluntarily consent to participate in this study\n* The participant is hospitalized or receiving outpatient care\n\nExclusion Criteria (patient):\n\n* Estimated survival prognosis by the physician is longer than 5 years\n* The participant is in a follow-up trajectory or in remission according to the physician\n* The participant is already receiving specialized palliative care known to the treating physician",true,{"count":58,"type":21},271,[24],"Cancer is one of the leading causes of death worldwide. In the care of people with cancer, it is essential to pay sufficient attention to individual care needs and quality of life. One component of non-cancer-directed care, care aimed at addressing symptoms independent of the cancer or tumor, may be palliative care. Palliative care can be initiated at any point along the disease trajectory and can therefore be provided simultaneously with tumor-directed care. When initiated in a timely manner, palliative care can significantly improve the quality of life of both the person living with a life-threatening condition and their family. Pain management and attention to physical, psychosocial, and spiritual needs are central to this approach. Research shows that people with cancer develop palliative care needs well before the terminal phase. Communication about care needs, and palliative care in particular, is therefore essential for the timely initiation of palliative care.\n\nHowever, to date, palliative care is often initiated too late or not at all, frequently resulting in suboptimal care during the final months of life. Communication about palliative care is postponed or avoided by both healthcare professionals and people with cancer. Efforts are being made at various levels to make palliative care more discussable and to initiate it in a timely manner. At present, however, these efforts primarily focus on the role of healthcare services and professionals. By focusing solely on healthcare providers, palliative care has not yet been fully integrated as a standard component of oncological practice. The literature indicates that, in addition to barriers, there are also opportunities at the level of the person with cancer when it comes to initiating a conversation about palliative care with their physician, provided that adequate support is available.\n\nThe health promotion approach, which focuses on the role of various personal and environmental factors in stimulating healthy behavior, is well suited to addressing this need for change in patient-initiated communication about palliative care. Health promotion makes use of theoretical behavioral models, for which evidence demonstrates that their application leads to more effective behavioral interventions and successful behavior change. These models have also been shown to be promising in promoting behaviors related to palliative care and in enhancing patient empowerment.",[27,62],"Cancer",[64,65,62,66,67,68,69,70,71],"Palliative Care","Early palliative care","Oncology","Patient-physician communication","Patient empowerment","Health promotion","Behavioral change","Quality of life","RECRUITING","2026-04-09",{"date":75,"type":40},"2026-04-14",{"date":77,"type":40},"2026-03-17",{"date":44,"type":21},{"name":80,"class":47},"University Hospital, Ghent",4,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100626807","home-based-physiotherapy-in-oncology-100626807","NCT07440433","Home-Based Physiotherapy in Oncology","Home-Based Physiotherapy for Oncology Patients: Feasibility and Acceptability of a Supervised Exercise Programme","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of solid cancer, undergoing or recently completed treatment.\n* Overall survival greater than 12 months, as judged by the treating oncologist\n* Clinically stable and deemed fit for moderate exercise by the treating oncologist\n* Able to use an exercise bike\n* Home environment suitable for delivery and installation of the exercise bike\n* Able to understand the study language and follow study instructions\n* Able to give a written informed consent\n\nExclusion Criteria:\n\n* Medical contraindication to moderate exercise (e.g. uncontrolled cardiac or pulmonary disease, recent myocardial infarction, severe anemia or acute infection, unstable bone metastases or high fracture risk)\n* Cognitive impairment preventing active participation\n* Physical inability to perform the prescribed exercise programme, including cycling and resistance exercises.\n* Participation in another intensive rehabilitation program\n* Any other condition that, in the opinion of the treating oncologist or investigator, makes participation unsafe or not feasible\n* Pregnant or lactating women.",{"count":90,"type":21},21,[24],"The goal of this clinical trial is to assess the feasibility, acceptability, and safety of a supervised home-based physiotherapy programme for adult oncology patients. The programme combines aerobic cycling exercise, resistance training, and mental preparation strategies, delivered at home with regular professional supervision.\n\nThe main questions this study aims to answer are:\n\nIs a 6-month supervised home-based physiotherapy programme feasible in terms of recruitment, adherence, and retention?\n\nIs the programme safe for oncology patients undergoing or having recently completed cancer treatment?\n\nIs the programme acceptable and satisfactory from the patient's perspective?\n\nHow do physical function and health-related quality of life change over the course of the programme?\n\nThis is a single-arm feasibility study with no comparison group.\n\nParticipants will:\n\nReceive a stationary exercise bike delivered and installed at their home\n\nFollow a 6-month individualized physiotherapy programme including:\n\nThree weekly sessions combining moderate-intensity cycling and resistance exercises\n\nWear a connected activity watch during exercise sessions to monitor heart rate and exercise duration\n\nReceive weekly supervision from oncology-trained physiotherapists through alternating in-person hospital visits and structured phone calls\n\nComplete physical function assessments and questionnaires on quality of life, fatigue, and programme satisfaction at baseline, mid-program, and study completion\n\nThe results of this study will inform the design of a future larger controlled trial and contribute to the development of accessible home-based rehabilitation programmes for oncology patients.",[94,27],"Rehabilitation Exercise","2026-02-25",{"date":97,"type":40},"2026-02-27",{"date":99,"type":21},"2026-03",{"date":101,"type":21},"2028-03",{"name":103,"class":47},"University Hospital, Geneva",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":104},"100622468","study-protocol-impact-of-metamizole-optalgin-on-anti-xa-concentrations-in-oncology-patients-receiving-doacs-100622468","NCT07384013","Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Inclusion Criteria:\n\n* Adult oncology patients (≥18 years old).\n* Receiving apixaban or rivaroxaban for anticoagulation.\n* New\u002Fcurrent metamizole users taking at least 1g TID for pain management.\n* Platelets ≥100×10⁹\u002FL\n* ECOG PS\\\u003C3\n* Provided informed consent\n\nExclusion Criteria:\n\n* History of allergic reaction to metamizole or DOACs.\n* Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT\u002Fzonda)",{"count":113,"type":21},30,[24],"Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)",[27,117,118],"Coagulation Defect","Pain Management",[120,121],"Direct Oral Anticoagulants (DOACs)","Optalgin","2026-01-26",{"date":124,"type":40},"2026-02-03",{"date":126,"type":40},"2025-11-01",{"date":128,"type":21},"2027-12-31",{"name":130,"class":47},"Rambam Health Care Campus",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":104},"100608851","analysis-of-the-determinants-of-the-participation-of-patients-and-health-professionals-of-the-university-hospital-center-of-martinique-in-clinical-research-protocols-in-medical-oncology-studyorec-100608851","NCT07206927","Analysis of the Determinants of the Participation of Patients and Health Professionals of the University Hospital Center of Martinique in Clinical Research Protocols in Medical Oncology (StudyOrec)","Analysis of the Determinants of the Participation of Patients and Health Professionals of the University Hospital Center of Martinique in Clinical Research Protocols in Medical Oncology","Inclusion Criteria for patients group:\n\n* Male or female,\n* Age ≥ 18 years,\n* Patient being treated for cancer at the University Hospital Center of Martinique,\n* Patient who can read and\u002For understand French,\n* Patient who has consented to the use of their medical data for this research.\n\nInclusion Criteria for professionals group:\n\n\\- Any qualified healthcare professional working in the medical oncology departments of the University Hospital Center of Martinique, such as oncologists, radiation therapists, urologists, nurses, etc.\n\nExclusion Criteria for patients group:\n\n* Patient with known cognitive impairments that prevent them from completing the questionnaire,\n* Subjects under legal protection (guardianship\u002Fcuratorship),\n* Subjects at an advanced stage of the disease (asthenia),\n* Written or oral objection from the patient to the use of data for research purposes.\n\nExclusion Criteria for professionals group:\n\n* Students in training regardless of their field,\n* Replacement healthcare professionals for a period of less than 12 months.",{"count":113,"type":21},"OBSERVATIONAL","For optimal patient care, it is imperative that healthcare professionals implement appropriate strategies. These strategies must take into account changes in healthcare practices associated with advances in medications and medical equipment. Clinical trials play a crucial role in validating the efficacy and safety of these advances, ensuring high-quality and constantly improving healthcare.\n\nHowever the proportion of patients included in therapeutic trials is often considered too low.\n\nSeveral ideas have been explored to explain the low participation rate in research projects. These are closely linked to research actors and tools, such as, for example:\n\n* the research protocol and its eligibility criteria, which may be overly strict\n* healthcare professionals with the barriers encountered in carrying out research programs (motivation, attitude and perceptions, human, logistical and technical constraints, lack of training)\n* patients who are generally poorly acculturated to clinical research, the lack of information for patients in healthcare services, and patients' lack of trust in the healthcare system.\n* ...\n\nIn Martinique, healthcare professionals face the same challenges in including patients in clinical trials.\n\nPatient inclusion is necessary due to the region's demographic and medical characteristics. To improve patient inclusion in these trials, it is important to define the human and material barriers and levers that influence the participation of patients and healthcare professionals in clinical research protocols in the medical oncology departments of the Martinique University Hospital.\n\nThe investigators believe that increased patient awareness of the benefits of clinical research, equally increased incentives for healthcare professionals, and the establishment of adequate support structures would increase participation in clinical research protocols within the medical oncology departments of the Martinique University Hospital.\n\nBy conducting a mixed qualitative and quantitative study to gather the perspectives of patients and caregivers, the investigators aim to identify the human and material barriers that limit the participation of oncology patients in Martinique.",[27,62,66],[143,144,145,146,147],"clinical research participation","investigation","interrogation","barriers and levers of participation","questionnaire","2025-09-26",{"date":150,"type":40},"2025-10-03",{"date":152,"type":21},"2025-10-01",{"date":154,"type":21},"2027-01-01",{"name":156,"class":47},"University Hospital Center of Martinique",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":5},"100606422","financial-toxicity-ft-for-radiotherapy-rt-patients-in-italy-a-yairo-associazione-italiana-radioterapia-e-ocologia-clinica-multicenter-study-100606422","NCT07175350","Financial Toxicity (FT) for Radiotherapy (RT) Patients in Italy: a yAIRO (Associazione Italiana Radioterapia e Ocologia Clinica) Multicenter Study","Valutazione Della \"Financial Toxicity\" Nei Pazienti Sottoposti a Radioterapia: Uno Studio Multicentrico Italiano Promosso da yAIRO (Associazione Italiana Radioterapia e Ocologia Clinica)","FIT-RT","Inclusion Criteria:\n\n* Patients older than 18 years of age.\n\nHistological diagnosis of malignancy for which the patient requires radiotherapy treatment.\n\nExclusion Criteria:\n\n* Patient refusal to complete the questionnaire.",{"count":166,"type":21},1000,"Non- profit, multicenter, prospective, observational study. The study aims to assess financial toxicity (FT) in patients undergoing radiotherapy for oncological diseases, assessed with a validated questionnaire (Patient Reported Outcome for Fighting FInancial Toxicity-PROFFIT- questionnaire).",[27],[27,170,171,172,173],"Radiotherapy","Financial toxicity","PROFFIT questionnaire","Quality of Life","2025-09-15",{"date":176,"type":40},"2025-09-16",{"date":178,"type":40},"2024-09-06",{"date":180,"type":21},"2026-06-01",{"name":182,"class":47},"Valerio Nardone",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":104},"100564265","implications-of-biological-and-procedural-factors-of-18-f-fdg-uptake-by-normal-organs-and-neoplastic-lesions-100564265","NCT06626932","Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions","Implications of Biological and Procedural Factors of 18-f FDG PET\u002FCT Uptake by Normal Organs and Neoplastic Lesions","Inclusion Criteria:\n\n* cancer patients referred to nuclear medicine unit\n\nExclusion Criteria:\n\n* patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs","1 Year","90 Years",{"count":193,"type":21},259,"To evaluate implications of biological and procedural factors of 18-f FDG PET\u002FCT uptake on normal organs and neoplastic lesions.",[27],[197],"18-f FDG PET\u002FCT","2024-10-02",{"date":200,"type":40},"2024-10-04",{"date":202,"type":21},"2024-10",{"date":204,"type":21},"2026-11",{"name":206,"class":47},"mahenoor alaa eldeen naem"]